NCPA welcomes Melinta Therapeutics to advisory council 

ALEXANDRIA, Va., and PARSIPPANY, N.J. – The National Home Infusion Association has announced that Melinta Therapeutics, a commercial-stage company providing therapies for acute and life-threatening illnesses, has joined its Future of Infusion Advisory Council (FIAC). The strategic advisory group, which is comprised of manufacturing and service companies invested in the home and alternate site infusion industry, works with association staff and the board of directors to address critical issues, challenges and opportunities. “We look forward to building on our long-standing partnership with Melinta through their engagement in FIAC,” said Connie Sullivan, NHIA president and CEO. “By collaborating with industry leaders in this way, we can improve upon the ways we mutually serve the infusion community, which helps more patients lead healthy, independent lives.” Membership in the FIAC provides Melinta with the opportunity for critical collaboration with the association and other organizations serving patients. This work helps to enhance continuity of care as patients transition out of the hospital, the company says. “We’re excited to join FIAC and collaborate with health care professionals on the patient experience both immediately and long-term,” said John Harlow, chief commercial officer at Melinta. “Through our partnership with NHIA, we have built a stronger understanding of the home infusion marketplace and customer needs, helping us address the changing landscape in outpatient infusion. Together, we can make a real difference in patient care – today and tomorrow.”